EuCorVac-19 is a COVID-19 vaccine candidate developed by EuBiologics Co. EuBiologics Co., Ltd started the study on February 23, 2021. The study is titled...
4 KB (260 words) - 19:08, 13 February 2024
be approved for the general population. For example, the CoronaVac, Covishield, BBIBP-CorV and Covaxin vaccines are not part of Australia's national vaccination...
322 KB (19,558 words) - 03:33, 16 September 2024
000 participants. BBIBP-CorV shares similar technology with CoronaVac and Covaxin, other inactivated virus vaccines for COVID-19. Its product name is SARS-CoV-2...
90 KB (8,570 words) - 16:40, 27 January 2024
26 July 2021. "Safety, Tolerance and Immunogenicity of EuCorVac-19 for the Prevention of COVID-19 in Healthy Adults". ClinicalTrials.gov. 5 March 2021....
95 KB (18,965 words) - 23:35, 15 September 2024
COVID-19 vaccination in South Korea is an ongoing immunization campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus...
21 KB (1,381 words) - 20:39, 16 May 2024
The COVID-19 pandemic in Nepal was part of the worldwide pandemic of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2...
180 KB (23,898 words) - 14:59, 19 August 2024
Sinopharm (company) (category COVID-19 vaccine producers)
000 participants. BBIBP-CorV shares similar technology with CoronaVac and BBV152, other inactivated virus vaccines for COVID-19. Peer-reviewed results...
17 KB (1,214 words) - 12:47, 25 August 2024
Sinopharm Group (section COVID-19 Vaccine development)
BIBP COVID-19 vaccine, also known as BBIBP-CorV, the Sinopharm COVID-19 vaccine, or BIBP vaccine, is one of two inactivated virus COVID-19 vaccines developed...
13 KB (888 words) - 09:53, 2 September 2024
SARS-CoV-2 Beta variant (redirect from 501.V2 COVID-19)
variant, (B.1.351), was a variant of SARS-CoV-2, the virus that causes COVID-19. One of several SARS-CoV-2 variants initially believed to be of particular...
72 KB (6,070 words) - 20:49, 10 September 2024
SARS-CoV-2 Delta variant (redirect from Indian COVID-19 strain)
Ranasinghe, Thushali; Dayarathne, Shashika (19 July 2021). "Antibody and T cell responses to Sinopharm/BBIBP-CorV in naive and previously infected individuals...
130 KB (12,297 words) - 20:50, 10 September 2024